Konstantin I. Karnoukh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Konstantin I. Karnoukh has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Natalia B. Lazareva
Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications - Evgenia Valerievna Shikh
I.M. Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - Svetlana V. Zhilina
Morozov Children’s City Clinical Hospital
1 shared publication - Vladimir N. Drozdov
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication Ших Евгения Валерьевна
Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)
1 shared publication
Latest Publications
- Open Access
- 15 July 2022
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 10 (3) , 269-282
Evaluation of the Rationality of Antibiotic Therapy of Nosocomial Infections in Resuscitation and Intensive Care Patients with COVID-19: a Retrospective Analysis
Оценка рациональности антибактериальной терапии внутрибольничных инфекций у пациентов в отделении реанимации и интенсивной терапии на фоне COVID-19: ретроспективный анализ
- 15 July 2022
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 10 (3) , 269-282
Open AccessEvaluation of the Rationality of Antibiotic Therapy of Nosocomial Infections in Resuscitation and Intensive Care Patients with COVID-19: a Retrospective Analysis
Оценка рациональности антибактериальной терапии внутрибольничных инфекций у пациентов в отделении реанимации и интенсивной терапии на фоне COVID-19: ретроспективный анализ
- 18 April 2022
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 77 (1) , 25-32
Etiology and Antimicrobial Resistance of Secondary Bacterial Infections in Patients Hospitalized with COVID-19: A Retrospective Analysis
Background. One of the complications in patients hospitalized with COVID-19 is a secondary bacterial infection. Its frequency can reach 15%, which makes it important to determine the etiology and antimicrobial resistance of the key pathogens responsible for the development of this pathology, in order to further improve the practice of prescribing and increase the effectiveness of antimicrobial chemotherapy. Aims to assess the etiological structure and antibiotic resistance of the main pathogens of SBIs to improve the practice of antibiotic prescription. Methods. This retrospective study reviewed medical records of the patients hospitalized with COVID-19 in the Moscow city hospital No. 4 between April 28 and November 1, 2020. Demographic, clinical outcomes, etiology, and antimicrobial resistance data of the SBIs were collected. Outcomes were also compared between patients who were classified as severe and critical on admission. Results. Among 3180 patients hospitalized with COVID-19, 220 (6.9%) patients had acquired SBIs, and 50.0% of cases were fatal. The mean age was 72.7 13.07 years. A higher mortality rate was observed in the group of critical patients (63%). 560 strains of bacteria isolated from the SBIs (58.8% isolated from lungs, 21% from urine and 20.2% from blood). 330 strains (58.9%) were Gram-negative bacteria. 109 patients had infections with mixed bacteria. 45 of them (20.5% of the total number of patients included in the study) had 2 pathogens, and 64 patients (29.1%) 3 or more strains. The top three bacteria of SBIs were A. baumannii (23.6%; 132/560), K. pneumoniae (22.9%; 128/560), and S. epidermidis (10.4%; 58/560). The isolation rates of carbapenem-resistant A. baumannii were 97%. Cefoperazone/sulbactam was the most active antibiotic against this pathogen with 62.1% sensitivity. Among K. pneumoniae strains, the level of resistance to carbapenems was 77.4% to meropenem and 54% to imipenem. The proportion of resistant strains to tigecycline and to colistin was 4 and 2.3% respectively. Meticillin resistance was present in 38.5% of S. aureus. 50% of E. faecium strains were vancomycin-resistant. Conclusions. Gram-negative bacteria, especially A. baumannii and K. pneumoniae, were the main pathogens, and the resistance rates of the major isolated bacteria were generally high, which indicates that more accurate use of antibacterial agents is necessary for SBIs in patients hospitalized with COVID-19.
- 18 April 2022
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 77 (1) , 25-32
Etiology and Antimicrobial Resistance of Secondary Bacterial Infections in Patients Hospitalized with COVID-19: A Retrospective Analysis
Background. One of the complications in patients hospitalized with COVID-19 is a secondary bacterial infection. Its frequency can reach 15%, which makes it important to determine the etiology and antimicrobial resistance of the key pathogens responsible for the development of this pathology, in order to further improve the practice of prescribing and increase the effectiveness of antimicrobial chemotherapy. Aims to assess the etiological structure and antibiotic resistance of the main pathogens of SBIs to improve the practice of antibiotic prescription. Methods. This retrospective study reviewed medical records of the patients hospitalized with COVID-19 in the Moscow city hospital No. 4 between April 28 and November 1, 2020. Demographic, clinical outcomes, etiology, and antimicrobial resistance data of the SBIs were collected. Outcomes were also compared between patients who were classified as severe and critical on admission. Results. Among 3180 patients hospitalized with COVID-19, 220 (6.9%) patients had acquired SBIs, and 50.0% of cases were fatal. The mean age was 72.7 13.07 years. A higher mortality rate was observed in the group of critical patients (63%). 560 strains of bacteria isolated from the SBIs (58.8% isolated from lungs, 21% from urine and 20.2% from blood). 330 strains (58.9%) were Gram-negative bacteria. 109 patients had infections with mixed bacteria. 45 of them (20.5% of the total number of patients included in the study) had 2 pathogens, and 64 patients (29.1%) 3 or more strains. The top three bacteria of SBIs were A. baumannii (23.6%; 132/560), K. pneumoniae (22.9%; 128/560), and S. epidermidis (10.4%; 58/560). The isolation rates of carbapenem-resistant A. baumannii were 97%. Cefoperazone/sulbactam was the most active antibiotic against this pathogen with 62.1% sensitivity. Among K. pneumoniae strains, the level of resistance to carbapenems was 77.4% to meropenem and 54% to imipenem. The proportion of resistant strains to tigecycline and to colistin was 4 and 2.3% respectively. Meticillin resistance was present in 38.5% of S. aureus. 50% of E. faecium strains were vancomycin-resistant. Conclusions. Gram-negative bacteria, especially A. baumannii and K. pneumoniae, were the main pathogens, and the resistance rates of the major isolated bacteria were generally high, which indicates that more accurate use of antibacterial agents is necessary for SBIs in patients hospitalized with COVID-19.
- Open Access
- 30 October 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 118-128
Analysis of the antibiotic consumption on the backdrop of the COVID-19 pandemic: hospital level
Introduction. According to available data, the frequency of prescribing antibacterial drugs to patients hospitalized with COVID-19 is many times higher than the level of bacterial infection recorded in them. This trend may make an extremely negative contribution to the problem of antibiotic resistance in the future, which makes it important to monitor and study the consumption of antibiotics in this category of patients.Aim of the study. To estimate the change in the consumption of antibacterial drugs in patients hospitalized with COVID-19 in a multidisciplinary hospital compared with the consumption in the pre-pandemic period, and to conduct a subsequent analysis of the detected changes.Materials and methods. This retrospective study, reviewed the medical records of patients hospitalized with COVID-19 in the Moscow city hospital No. 4 in the period from April 27 to December 31, 2020, as well as medical records of patients hospitalized in the same medical institution for the same period of 2019. Results of the use of antibacterial drugs were obtained. They were evaluated using the ATC/DDD methodology and then subjected to further analysis.Results. Total consumption increased from 31,576 DDD/100 bed-days to 220,609 DDD/100 bed-days among the patients hospitalized with COVID-19. The level of consumption of macrolides increased most significantly – from 0.024 DDD/100 bed-days to 147.898 DDD/100 bed-days. The level of consumption of penicillins increased from 2,346 DDD/100 bed-days to 15,892 DDD/100 beddays, cephalosporins – from 11.78 DDD/100 bed-days to 19,107 DDD/100 bed-days, fluoroquinolones – from 10,276 DDD/100 beddays to 25,535 DDD/100 bed-days.Conclusion. The consumption of antibiotics has increased dramatically on the backdrop of the COVID-19 pandemic. Based on the data of the frequency of bacterial complications in patients with COVID-19 (no more than 8%), a more rational approach to antibacterial therapy in this group of patients is needed to reduce the potential deterioration of the problem of antibiotic resistance.
- 30 October 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 118-128
Open AccessAnalysis of the antibiotic consumption on the backdrop of the COVID-19 pandemic: hospital level
Introduction. According to available data, the frequency of prescribing antibacterial drugs to patients hospitalized with COVID-19 is many times higher than the level of bacterial infection recorded in them. This trend may make an extremely negative contribution to the problem of antibiotic resistance in the future, which makes it important to monitor and study the consumption of antibiotics in this category of patients.Aim of the study. To estimate the change in the consumption of antibacterial drugs in patients hospitalized with COVID-19 in a multidisciplinary hospital compared with the consumption in the pre-pandemic period, and to conduct a subsequent analysis of the detected changes.Materials and methods. This retrospective study, reviewed the medical records of patients hospitalized with COVID-19 in the Moscow city hospital No. 4 in the period from April 27 to December 31, 2020, as well as medical records of patients hospitalized in the same medical institution for the same period of 2019. Results of the use of antibacterial drugs were obtained. They were evaluated using the ATC/DDD methodology and then subjected to further analysis.Results. Total consumption increased from 31,576 DDD/100 bed-days to 220,609 DDD/100 bed-days among the patients hospitalized with COVID-19. The level of consumption of macrolides increased most significantly – from 0.024 DDD/100 bed-days to 147.898 DDD/100 bed-days. The level of consumption of penicillins increased from 2,346 DDD/100 bed-days to 15,892 DDD/100 beddays, cephalosporins – from 11.78 DDD/100 bed-days to 19,107 DDD/100 bed-days, fluoroquinolones – from 10,276 DDD/100 beddays to 25,535 DDD/100 bed-days.Conclusion. The consumption of antibiotics has increased dramatically on the backdrop of the COVID-19 pandemic. Based on the data of the frequency of bacterial complications in patients with COVID-19 (no more than 8%), a more rational approach to antibacterial therapy in this group of patients is needed to reduce the potential deterioration of the problem of antibiotic resistance.
- Open Access
- 22 November 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 17,p. 114-122
Herbal medicines: current use in the treatment of respiratory infections
The article investigates the causes and mechanisms of coughing and the treatment choice. Phytotherapy has a special role in the treatment of acute respiratory infections. Biologically active substances of plants integrate into metabolic processes more naturally, treatment with herbal medicines is distinguished by better tolerance, lower frequency of side effects and complications. High biological activity and a wide therapeutic index (the relationship between toxic and therapeutic dosing) can also be designated as advantages of medicinal plants. The article presents research data showing the miscellaneous effects of herbal medicines on the pathogenesis of cough: sputum production, improving the drainage function of the bronchi, as well as antimicrobial effect. The article discusses the pharmacological properties of drugs containing combinations of herbal extracts as active ingredients: thyme, ivy and primrose. Thyme has anti-inflammatory, antiviral and antibacterial effects due to blocking the growth of various strains of bacteria and fungi. Ivy leaf extract is characterized by similar properties. Primrose root extract has expectorant, secretolytic, anti-inflammatory and antiviral properties. It is important to note that the use of a combination of extracts provides a more significant clinical effect compared to the sum of the effects of the individual ingredients. A review of key clinical studies confirming the effectiveness of the use of combinations of thyme, ivy and primrose extracts (approved for medical use in the Russian Federation in the form of drugs Bronchipret and Bronchipret TP) in adults and children for cough and other symptoms of acute respiratory infections treatment. The compatibility of herbal medicines with other drugs for the treatment of respiratory pathology has been noted.
- 22 November 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 17,p. 114-122
Open AccessHerbal medicines: current use in the treatment of respiratory infections
The article investigates the causes and mechanisms of coughing and the treatment choice. Phytotherapy has a special role in the treatment of acute respiratory infections. Biologically active substances of plants integrate into metabolic processes more naturally, treatment with herbal medicines is distinguished by better tolerance, lower frequency of side effects and complications. High biological activity and a wide therapeutic index (the relationship between toxic and therapeutic dosing) can also be designated as advantages of medicinal plants. The article presents research data showing the miscellaneous effects of herbal medicines on the pathogenesis of cough: sputum production, improving the drainage function of the bronchi, as well as antimicrobial effect. The article discusses the pharmacological properties of drugs containing combinations of herbal extracts as active ingredients: thyme, ivy and primrose. Thyme has anti-inflammatory, antiviral and antibacterial effects due to blocking the growth of various strains of bacteria and fungi. Ivy leaf extract is characterized by similar properties. Primrose root extract has expectorant, secretolytic, anti-inflammatory and antiviral properties. It is important to note that the use of a combination of extracts provides a more significant clinical effect compared to the sum of the effects of the individual ingredients. A review of key clinical studies confirming the effectiveness of the use of combinations of thyme, ivy and primrose extracts (approved for medical use in the Russian Federation in the form of drugs Bronchipret and Bronchipret TP) in adults and children for cough and other symptoms of acute respiratory infections treatment. The compatibility of herbal medicines with other drugs for the treatment of respiratory pathology has been noted.